ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.
HER2 immunohistochemistry
breast cancer
in situ hybridisation
Journal
Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
24
11
2018
revised:
24
01
2019
accepted:
03
02
2019
pubmed:
12
5
2019
medline:
4
12
2019
entrez:
12
5
2019
Statut:
ppublish
Résumé
The latest update to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing in breast cancer guidelines was published in 2018. A multidisciplinary expert committee, convened under the auspices of the Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting framework, evaluated the implications of these guidelines for clinical practice in Australia. Following feedback from professional bodies, including the RCPA and CanSAC, peer review was invited. The final document prepared by the authors, endorsed by the Expert Committee RCPA Structured Pathology Reporting of Breast Cancer and by CanSAC, is published herein.
Identifiants
pubmed: 31076089
pii: S0031-3025(18)30615-9
doi: 10.1016/j.pathol.2019.02.004
pii:
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-348Informations de copyright
Copyright © 2019 Royal College of Pathologists of Australasia. All rights reserved.